Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11 2020 - 4:30PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the development and commercialization of a
late-stage pipeline of novel therapies for debilitating liver
diseases, today announced that on September 10, 2020, the
Compensation Committee of Mirum’s Board of Directors granted
non-qualified stock option awards to purchase an aggregate of
103,700 shares of common stock to five new employees under Mirum’s
2020 Inducement Plan. The Compensation Committee of Mirum’s Board
of Directors approved the awards as an inducement material to the
new employees’ employment in accordance with Nasdaq Listing Rule
5635(c)(4).
Each stock option has an exercise price per share equal to
$19.54 per share, Mirum’s closing trading price on September 10,
2020, and will vest over four years, with 25% of the underlying
shares vesting on the one-year anniversary of the applicable
vesting commencement date and the balance of the underlying shares
vesting monthly thereafter over 36 months, subject to the new
employees’ continued service relationship with Mirum through the
applicable vesting dates. The awards are subject to the terms and
conditions of Mirum’s 2020 Inducement Plan and the terms and
conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. The company’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS), progressive familial intrahepatic
cholestasis (PFIC), and biliary atresia. The company has initiated
a rolling NDA submission for maralixibat in the treatment of
patients with cholestatic pruritus associated with ALGS and expects
to complete the submission in the first quarter of 2021.
Additionally, the company plans to submit a marketing authorization
application to the European Medicines Agency for maralixibat in the
treatment of patients with PFIC2 in the fourth quarter 2020.
The company is also developing volixibat, also an oral
ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic
cholestasis of pregnancy. For more information, visit
MirumPharma.com. Follow Mirum on Twitter, Facebook and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005102/en/
Investor Contact: Ian Clements, Ph.D.
ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024